Journal article
Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: A phase 1b study
D Kotasek, N Tebbutt, J Desai, S Welch, LL Siu, S McCoy, YN Sun, J Johnson, AH Adewoye, T Price
BMC Cancer | BMC | Published : 2011
Abstract
Background: This phase 1b study assessed the maximum tolerated dose (MTD), safety, and pharmacokinetics of motesanib (a small-molecule antagonist of VEGF receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit) administered once daily (QD) or twice daily (BID) in combination with erlotinib and gemcitabine in patients with solid tumors.Methods: Patients received weekly intravenous gemcitabine (1000 mg/m2) and erlotinib (100 mg QD) alone (control cohort) or in combination with motesanib (50 mg QD, 75 mg BID, 125 mg QD, or 100 mg QD; cohorts 1-4); or erlotinib (150 mg QD) in combination with motesanib (100 or 125 mg QD; cohorts 5 and 6).Results: Fifty-six patients were enrolled ..
View full abstractGrants
Funding Acknowledgements
The authors would like to acknowledge Bernd Brunner, PhD, and Cindy Wake, BS, for support of the motesanib and erlotinib bioanalytical analysis and sample coordination; Rebeca Melara, MS, and Jian-Feng Lu, PhD, for contributions to the pharmacokinetic analysis; and Erik Rasmussen, MS, for statistical support. Additionally, the authors would like to thank Benjamin Scott, PhD, and Ali Hassan, PhD (Complete Healthcare Communications, Inc., Chadds Ford, PA), whose work was funded by Amgen Inc., for assistance in writing this manuscript.